Biogen Abandons Aducanumab, Pivots Focus to Lecanemab for Alzheimer Disease

Aducanumab’s accelerated approval was controversial and insurance coverage was limited of the expensive therapy.

Related Keywords

New York ,United States ,American ,Eli Lilly ,Aducanumab Aduhelm ,Institute For Clinical ,New York Times ,Coverage Determination ,American Journal ,Alzheimer Disease ,Aducanumab ,Lecanumab ,